BRAF and neoplasm: Based on 2022 guidelines from the American Society of Clinical Oncology, the decision to initiate anti-EGFR treatment should be guided by the primary tumor location and testing for BRAF and RAS (KRAS and NRAS) mutations and deficient mismatch repair or MSI2.